39
Participants
Start Date
December 19, 2022
Primary Completion Date
January 9, 2025
Study Completion Date
January 9, 2025
LYL845
LYL845 is an autologous tumor infiltrating lymphocyte (TIL) enhanced via Epi-R, a proprietary epigenetic reprogramming technology
Allegheny General Hospital, Pittsburgh
Georgetown University, Washington D.C.
Duke University Medical Center, Durham
Ohio State University Medical Center, Columbus
University of Iowa Hospitals and Clinics, Iowa City
Mayo Clinic Comprehensive Cancer Center, Rochester
University of Texas Southwestern Medical Center, Dallas
Huntsman Cancer Institute at University of Utah, Salt Lake City
UCLA Medical Center, Santa Monica
Stanford University, Stanford
UC Davis Coomprehensive Cancer Center, Sacramento
Oregon Health Sciences University, Portland
Fred Hutchinson Cancer Center, Seattle
Yale Cancer Center, Yale University, New Haven
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Hackensack Meridian Health Inc, Hackensack
Rutgers Cancer Institute of New Jersey, New Brunswick
Lead Sponsor
Lyell Immunopharma, Inc.
INDUSTRY